Compare HTCR & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTCR | PHGE |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Japan | United States |
| Employees | N/A | 57 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 7.5M |
| IPO Year | 2022 | N/A |
| Metric | HTCR | PHGE |
|---|---|---|
| Price | $3.23 | $0.71 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 52.6K | ★ 299.8K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | ★ 87.84% | N/A |
| EPS Growth | ★ 414.29 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $30,407,229.00 | N/A |
| Revenue This Year | $123.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.84 | ★ N/A |
| Revenue Growth | ★ 39.19 | N/A |
| 52 Week Low | $0.15 | $0.25 |
| 52 Week High | $3.97 | $8.50 |
| Indicator | HTCR | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 60.89 | 22.34 |
| Support Level | $0.30 | $0.43 |
| Resistance Level | $3.97 | $2.35 |
| Average True Range (ATR) | 0.35 | 0.16 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 54.59 | 5.43 |
HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).